One observation that could be related to its low reported frequency in cancer is the finding of low expression levels of this mutation in transfected mammalian cells (compared to FGFR3 N540K, K650E or WT) (Figure 4) that might compromise its impact or could require additional changes in cancer cells to increase its stability or expression. This evidence concerns the gene FGFR3 and cancer.